| Prev Close | 0.87 |
| Open | 0.87 |
| Day Low/High | 0.85 / 0.87 |
| 52 Wk Low/High | 0.71 / 2.25 |
| Volume | 67.77K |
| Avg Volume | 439.40K |
| Exchange | NASDAQ |
| Shares Outstanding | 95.61M |
| Market Cap | 83.18M |
| EPS | -0.30 |
| P/E Ratio | N/A |
| Div & Yield | N.A. (N.A) |
Latest News
BioLineRx To Report First Quarter 2017 Results On May 25, 2017
Management to hold a conference call at 10:00 a.m. EDT
BioLineRx Announces Acquisition Of Agalimmune Ltd. To Accelerate Expansion Of Immuno-Oncology Pipeline
Agalimmune's Lead Asset, AGI-134, Provides a Unique Approach for Eliciting Patient-specific, Anti-tumor Immune Responses in Multiple Cancer Types
BioLineRx To Report Annual 2016 Results On March 23, 2017
Management to hold a conference call at 9:00 a.m. EDT
BioLineRx Announces Initiation Of Immuno-Oncology Phase 2 Study To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
Study is part of strategic research collaboration between MSD and MD Anderson Cancer Center aimed to evaluate KEYTRUDA in selected GI tumors using various combinations
BioLineRx In-licenses Novel Anti-Inflammatory Treatment For Dry Eye Syndrome Under Strategic Collaboration With Major Global Pharmaceutical Company
Therapeutic compound is third project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates
BioLineRx To Report Third Quarter Results On November 22, 2016
Management to hold conference call at 10:00 a.m. EST
BioLineRx (BLRX) Stock Soars on Liver Drug Licensing Agreement
BioLineRx (BLRX) signed a licensing agreement with two Israeli companies to allow the development of a drug that treats liver failure conditions.
BioLineRx Announces In-licensing Of Novel Treatment For Liver Failure Conditions Under Strategic Collaboration
Therapeutic compound is second project in-licensed under strategic collaboration with Novartis for screening and development of novel drug candidates
BioLineRx Ltd. Presents Corporate Objectives At Investor Breakfast Meeting In NY
- Presentation includes details of 2017 operating plan and five-year Company vision -
BioLineRx Presents Final Results From Phase 2a Trial For Relapsed/Refractory AML At SOHO Conference
Combination of BL-8040 with Ara-C in difficult-to-treat patient population demonstrated substantial improvement over clinical response rates historically achieved with Ara-C
BioLineRx Announces Clinical Research Collaboration To Investigate Combination Of BL-8040 With Atezolizumab In Multiple Oncology Indications
Cancer immunotherapy collaboration with Genentech includes several Phase 1b combination studies for multiple solid tumor indications and AML
BioLineRx And I-Bridge Capital Establish A New Drug Development Joint Venture In China
JV will promote development and commercialization of Israeli-sourced therapeutic assets for Chinese healthcare market
BioLineRx Signs Second Clinical Immuno-Oncology Collaboration Agreement To Investigate Combination Of BL-8040 And KEYTRUDA® For Pancreatic Cancer
- Phase 2 study is part of strategic clinical research collaboration between MSD and MD Anderson Cancer Center aimed at evaluating KEYTRUDA in selected GI tumors using various combinations -